Merck (MRK) hikes outlook for 2024 as Q1 print beats analyst estimates
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/28/2026
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
- Stock action shows confidence in central banks: BofA’s Hartnett
- Oil prices slide about 2% as US, Iran explore path out of war
- Why stocks held up despite rising yields and $100 oil? These 2 words explain it
- Barclays asks if equity markets are nearing the boiling point
- White House blocks CNN from Air Force One trip, Washington Post reports
- Merck and Daiichi Sankyo withdraw lung cancer drug application
- Exclusive-SK Hynix's Solidigm weighs IPO that could value the unit at up to $150 billion, sources say
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
- Fox Factory sells Marucci Sports for $225M, cuts debt
Merck (MRK) Tops Q1 EPS by 14c, Beats on Revenue; Offers FY24 Guidance
April 25, 2024 6:33 AM EDTMerck (NYSE: MRK) reported Q1 EPS of $2.07, $0.14 better than the analyst estimate of $1.93. Revenue for the quarter came in at $15.8 billion versus the consensus estimate of $15.22 billion.
GUIDANCE:
Merck sees FY2024 EPS of $8.53-$8.65, versus the consensus of $8.56. Merck sees... More
